Phase I Randomized, Open-label, Parallel-controlled, Pharmacokinetic and Safety Study of BR201 Injection Versus Cosentyx in Healthy Male Subjects - Trial NCT06126718
Access comprehensive clinical trial information for NCT06126718 through Pure Global AI's free database. This Phase 1 trial is sponsored by BioRay Pharmaceutical Co., Ltd. and is currently Not yet recruiting. The study focuses on Psoriasis. Target enrollment is 88 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
BioRay Pharmaceutical Co., Ltd.
Timeline & Enrollment
Phase 1
Nov 01, 2023
Aug 01, 2024
Primary Outcome
AUC0-inf,Cmax
Summary
This is a randomized, open-label, controlled Phase I study of BR201 administered by
 subcutaneous injection. This study will characterize the pharmacokinetic, safety and
 immunogenicity of BR201 versus Cosentyx๏ผSecukinumab ๏ผ in healthy male subjects after a single
 dose.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06126718
Non-Device Trial